ERBB2 and breast carcinoma: However, this finding did not validate when testing APOBEC associated signatures in pre-treatment tumour biopsy samples from the external Sammut et al., (2022) (Fig. 4h; Supplementary Fig. 7) or the LeSurf et al., (2017) HER2+ breast cancer cohorts (Supplementary Fig. 8).